1 / 37

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease. Diabetes in Cardiology Cohorts. High Residual Risk of Diabetes: Observations from the Statin Trials. Mortality Impact of Glycemic Control: UGDP. Blood Glucose and Vascular Risk in Diabetes: UKPDS Findings.

keefe-cooley
Download Presentation

Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Early Type 2 Diabetes Mellitus: A Cardiovascular Disease

  2. Diabetes in Cardiology Cohorts

  3. High Residual Risk of Diabetes: Observations from the Statin Trials

  4. Mortality Impact of Glycemic Control: UGDP

  5. Blood Glucose and Vascular Risk in Diabetes: UKPDS Findings

  6. UKPDS Metformin Sub-Study: CHD Events

  7. Off Target Adverse Drug Effects

  8. ADOPT: Cardiovascular events

  9. Summary of RCT & Meta-Analysis Data on TZDs and MI Risk

  10. CV Effects of More Intensive Glucose Control in Recent Large-Scale Trials

  11. 2009 ADA/AHA/ACC Statement Recommendations

  12. Cautions for Diabetes Medications in CHD Patients: Beware the Product Label

  13. Proposed Algorithm for Glucose Treatment in T2DM Patients With/At risk for CVD

  14. Proposed Algorithm for Glucose Treatment in T2DM Patients With/At risk for CVD

  15. 2012 Guidance from ADA/EASD for Glucose Management

  16. ORIGIN Key Results

  17. Converging Pressures for Regulatory Change: Beyond A1C

  18. Summary of Revised Guidance for Diabetes Drug Development

  19. New FDA Regulatory Guidance for Drugs for Type 2 Diabetes

  20. Present Landscape of CVD Outcomes Trials in Type 2 DM

  21. SAVOR-TIMI 53 Summary

  22. SAVOR-TIMI 53 Summary

  23. EXAMINE

  24. EXAMINE

  25. Conclusions

  26. Abbreviations

  27. Abbreviations (cont)

  28. Abbreviations (cont)

  29. Abbreviations (cont)

  30. References

  31. References (cont)

  32. References (cont)

  33. References (cont)

  34. References (cont)

  35. References (cont)

  36. References (cont)

More Related